HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NAGE
Niagen Bioscience Inc
NAGE's fundamentals are weak: its operating margin fell 12 points to 3.9% and free cash flow fell 77%. At 18x earnings, it's trading below its usual 28x. Analysts expect earnings to fall sharply, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NAGE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Strong |
NAGE's balance sheet is currently strong, and its profitability is stable, but its revenue and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NAGE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $2.05 | -3.7% |
| Current | 18x | $2.13 | — |
| Fair | 27x | $3.30 | +55% |
| Expensive | 79x | $9.47 | +345% |
| Forward | 217x | $2.13 | — |
Historical ranges are pointers, not guarantees.
NAGE's PE is in its cheap range at 18x. Analysts expect earnings to fall, which would put today's price at 217x next year's earnings, in its expensive range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
HIMS has the edge over NAGE on the outlook, with more favorable revenue and profitability expectations.
NAGE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect NAGE's earnings and profitability to decline, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NAGE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.01 | -92% |
| Q3 2026 | $0.12 | -52% |
| Q2 2026 | $0.18 | -18% |
| Q1 2026 | $0.21 | +17% |
| Q4 2025 | $0.20 | +82% |
| Q3 2025 | $0.25 | +2400% |
| Q2 2025 | $0.22 | +$0.24 |
| Q1 2025 | $0.18 | +$0.23 |
| Q4 2024 | $0.11 | +$0.18 |
NAGE has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NAGE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NAGE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $27.2M | -20% |
| Q2 2026 | $29.8M | -4.3% |
| Q1 2026 | $31.5M | +3.3% |
| Q4 2025 | $33.8M | +16% |
| Q3 2025 | $34M | +33% |
| Q2 2025 | $31.1M | +37% |
| Q1 2025 | $30.5M | +38% |
| Q4 2024 | $29.1M | +37% |
NAGE's revenue fell from its 2025 peak and has held roughly level since: $27M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.8% | -18 points |
| Q2 2026 | 2.4% | -7.9 points |
| Q1 2026 | 5% | -11 points |
| Q4 2025 | 12% | -12 points |
| Q3 2025 | 12% | +6.2 points |
| Q2 2025 | 10% | +11 points |
| Q1 2025 | 16% | +19 points |
| Q4 2024 | 24% | +25 points |
NAGE has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NAGE on cash flow, with more consistent year-over-year improvement.
NAGE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6M | -29% |
| Q2 2026 | $2.8M | +122% |
| Q1 2026 | -$1.2M | -115% |
| Q4 2025 | $679K | -92% |
| Q3 2025 | $3.7M | +5.6% |
| Q2 2025 | $1.3M | +$1.5M |
| Q1 2025 | $7.9M | +2572% |
| Q4 2024 | $8.6M | +1222% |
NAGE still generates free cash flow, though less than at its 2024 peak: $5M over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NAGE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.1% | -3.4M shares |
| 1 year | -8.6% | -7.5M shares |
| 3 years | +5.5% | +4.1M shares |
| 5 years | +16% | +10.9M shares |
| Available history | +28% | +17.5M shares |
NAGE has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $2.8M |
| Q1 2026 | $2.4M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NAGE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -11.9x | Net Cash |
| Q2 2026 | -5.8x | Net Cash |
| Q1 2026 | -4.8x | Net Cash |
| Q4 2025 | -3.8x | Net Cash |
| Q3 2025 | -3.2x | Net Cash |
| Q2 2025 | -3.5x | Net Cash |
| Q1 2025 | -4.0x | Net Cash |
| Q4 2024 | -5.2x | Net Cash |
NAGE has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NAGE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 3.5 | Oversold |
NAGE's weekly RSI is 23 (oversold) and its Stochastic is 4 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NAGE PE vs Healthcare Sector
| Metric | NAGE | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 22 | 29 | 7 pts below |
NAGE is trading at 18x earnings, a 31% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NAGE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.50 | 15% below |
| 20 week MA | $2.93 | 27% below |
| 50 week MA | $4.14 | 49% below |
| 100 week MA | $6.23 | 66% below |
| 200 week MA | $4.35 | 51% below |
NAGE is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NAGE on returns for 2026, with the stronger performance.
NAGE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.47 | $4.99 | +12% |
| 2021 | $4.99 | $4.13 | -17% |
| 2022 | $4.13 | $1.50 | -64% |
| 2023 | $1.50 | $1.43 | -4.7% |
| 2024 | $1.43 | $5.52 | +286% |
| 2025 | $5.52 | $6.64 | +20% |
| 2026 YTD | $6.64 | $2.13 | -68% |
NAGE's yearly returns have swung widely, from +286% in 2024 to −64% in 2022. It's down 68% so far in 2026.